Teva Pharmaceutical Industries (NYSE: TEVA) reported earnings on Nov. 1. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended Sep. 30 (Q3), Teva Pharmaceutical Industries met expectations on revenues and beat slightly on earnings per share.

Compared to the prior-year quarter, revenue grew and GAAP earnings per share dropped to a loss.

Gross margins increased, operating margins dropped, net margins dropped.

Revenue details
 Teva Pharmaceutical Industries reported revenue of $4.97 billion. The 23 analysts polled by S&P Capital IQ anticipated a top line of $5.04 billion on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $4.34 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $1.28. The 25 earnings estimates compiled by S&P Capital IQ anticipated $1.25 per share. GAAP EPS were -$0.09 for Q3 against $1.03 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 52.3%, 20 basis points better than the prior-year quarter. Operating margin was -1.2%, 2,700 basis points worse than the prior-year quarter. Net margin was -1.6%, 2,270 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $5.29 billion. On the bottom line, the average EPS estimate is $1.36.

Next year's average estimate for revenue is $20.50 billion. The average EPS estimate is $5.37.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,474 members out of 2,545 rating the stock outperform, and 71 members rating it underperform. Among 542 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 537 give Teva Pharmaceutical Industries a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $50.28.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Teva Pharmaceutical Industries. Learn how to maximize your investment income and get "The 3 DOW Stocks Dividend Investors Need." Click here for instant access to this free report.